Anixa's CAR-T Pioneer to Keynote SCTR Retreat, Highlighting Ovarian Cancer Trial
Event summary
- Dr. Jose Conejo-Garcia, co-inventor of Anixa's FSHR-mediated CAR-T technology, will keynote the SCTR 2026 Retreat on March 6, 2026.
- Presentation will discuss Anixa's ongoing Phase 1 trial of lira-cel for recurrent ovarian cancer.
- Lira-cel targets follicle-stimulating hormone receptor (FSHR), selectively expressed on ovarian cells and tumor vasculature.
- Trial (NCT05316129) enrolls adult women with recurrent ovarian cancer who have progressed after at least two prior therapies.
The big picture
Anixa's keynote at the SCTR Retreat underscores the strategic importance of its FSHR-mediated CAR-T technology in ovarian cancer treatment. The company's collaborative model with top research institutions positions it to navigate the competitive oncology landscape, though success will depend on demonstrating clinical efficacy in ongoing trials. The focus on cell-based therapies aligns with broader industry trends toward targeted immunotherapies.
What we're watching
- Trial Progress
- How the Phase 1 trial results will validate Anixa's FSHR-mediated CAR-T approach.
- Industry Collaboration
- Whether Anixa can leverage partnerships with Moffitt and Cleveland Clinic to accelerate development.
- Market Differentiation
- The pace at which Anixa can establish lira-cel as a differentiated therapy in the competitive ovarian cancer space.
Related topics